Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer

Clinical trial NCT00515866 · COMPLETED

Trial details

NCT number: NCT00515866
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Pancreatic Neoplasms

Start date: 2007-08-01
Primary completion: 2011-10-01
Enrollment: 68

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.